First Trial of DBS for Stroke Rehabilitation: Insights on the Underlying Science (Video)

Investigator speaks to potential applications beyond stroke

dbscaptur2e

As previously reported on this blog, Cleveland Clinic researchers have launched the first clinical trial to examine the use of deep brain stimulation (DBS) to promote motor function recovery in disabled stroke survivors. The trial, launched in 2016 (a DBS device was implanted in the first patient in December), was awarded nearly $5 million in funding from the NIH’s Brain Research through Advancing Innovative Neurotechnologies (BRAIN) initiative.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

The trial’s lead investigator, neurosurgeon Andre Machado, MD, PhD, recently shared some insights on the trial’s clinical implications in this video post. Dr. Machado explains the essentials of the trial, which patients are candidates, and how DBS for stroke recovery differs from neuromodulation for movement disorders.

“Our primary hypothesis is that by applying DBS to the connections between the cerebellum and cerebral cortex, we can facilitate the plasticity that occurs in the cortex around the stroke and thereby promote recovery of function beyond what physical therapy alone can do,” Dr. Machado notes. “We need more and better options to help the many patients who remain chronically disabled after a stroke.”

Now co-investigator Kenneth Baker, PhD, assistant staff in Cleveland Clinic’s Department of Neurosciences, speaks to some of the scientific implications of the study’s attempt to stimulate the brain’s dentatothalamocortical pathway to restore lost motor function. He also explains how Cleveland Clinic’s recent NIH BRAIN grant award is supporting the team’s work.

Advertisement

“We know that deep cerebellar stimulation promotes motor recovery in a preclinical model of cortical stroke,” says Dr. Baker. “Our goal is to advance this therapy to promote recovery of motor function in humans. This has the potential to be a significant advancement for the field.”

Check out his insights in the video below.

Related Articles

23-NEU-3516858-brain-trauma-650×450
Neurotrauma Guidelines: Where They’ve Been, Where They’re Headed and How to Make the Most of Them

Q&A with Brain Trauma Foundation guideline architect Gregory Hawryluk, MD, PhD

20-NEU-2020111 neuroimmunology_650x450
Autoimmune Neurologic Disorders: Treatable Conditions That Should Not Be Missed

Q&A with newly arrived autoimmune neurology specialist Amy Kunchok, MD

20-NEU-1984276 multimodal-monitoring_650x450
Multimodal Monitoring in the Neuro ICU: Essentials for Clinicians (Podcast)

A neurocritical care specialist shares what’s spurring growth of this new evaluation approach

central vein sign in multiple sclerosis
New Frontiers in Diagnosing and Monitoring Multiple Sclerosis (Podcast)

Get ready for central vein sign and optical coherence tomography

20-NEU-1938374-migraine_650x450
CGRP Antagonists for Decreasing Migraine Frequency: A Primer

How these new drugs fit into practice two years out from their first approvals

20-NEU-1892171 CQD_650x450_CCC-1901608_06-03-20_0443
What’s Afoot and What’s Ahead for Physical Medicine and Rehabilitation

A conversation on the state of physiatry with the AAPM&R’s Vice President

Ad